SCHEMBL6076726

SCHEMBL6076726

CN(CCCc1ccc(Cl)c(Cl)c1)C(=O)C=C1OC(C)(C)OC1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
PDPK1 O15530 1/20 0.37
SIGMAR1 Q99720 11/20 0.36
TP53 P04637 2/20 0.36
CYP1A2 P05177 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
USP30 Q70CQ3 1/20 0.36
IGF1R P08069 1/20 0.35
ALOX15 P16050 1/20 0.35
SMYD2 Q9NRG4 1/20 0.35
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
PYGL P06737 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6077313 0.87 USP30 (0.47) PDPK1SIGMAR1ALDH1A1USP30TSHR
SCHEMBL6077308 0.87 USP30 (0.47) PDPK1SIGMAR1ALDH1A1USP30TSHR
SCHEMBL6879362 0.87 CDK8 (0.36) CDK8CLK4PDPK1SIGMAR1TP53
SCHEMBL6078367 0.87 CDK8 (0.36) CDK8CLK4PDPK1SIGMAR1TP53
SCHEMBL6077360 0.85 TRPV1 (0.41) PDPK1SIGMAR1
SCHEMBL6077362 0.85 TRPV1 (0.41) PDPK1SIGMAR1
SCHEMBL6078542 0.84 ALDH1A1 (0.37) MEN1ALDH1A1MAPTKMT2ATSHR
SCHEMBL6417431 0.81 POLB (0.38) PDPK1TP53MEN1ALDH1A1MAPT
SCHEMBL6417430 0.81 POLB (0.38) PDPK1TP53MEN1ALDH1A1MAPT
SCHEMBL6077948 0.80 LIPG (0.45) PYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7109186-B2 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-19 US disclosed
US-20040110804-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-10 US disclosed
WO-2004004657-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110804-A1 HIV integrase inhibitors CDKN1A, SAMHD1, CTCF CDK8 119/4885CLK4 4290/4885PDPK1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.